Cardlytics Inc (NASDAQ:CDLX) Director David Leslie Adams Sells 23,750 Shares
Cardlytics Inc (NASDAQ:CDLX) Director David Leslie Adams sold 23,750 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $58.75, for a total transaction of $1,395,312.50. Following the transaction, the director now directly owns 41,770 shares of the company’s stock, valued at approximately $2,453,987.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Cardlytics stock opened at $61.72 on Wednesday. The company has a market cap of $1.28 billion, a PE ratio of -28.84 and a beta of 1.71. The firm has a fifty day moving average price of $46.78 and a two-hundred day moving average price of $33.98. Cardlytics Inc has a fifty-two week low of $9.80 and a fifty-two week high of $61.98.
Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.31. The company had revenue of $56.42 million for the quarter, compared to the consensus estimate of $50.02 million. Cardlytics had a negative net margin of 17.01% and a negative return on equity of 44.53%. The business’s revenue was up 63.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.15) EPS. As a group, analysts forecast that Cardlytics Inc will post -1.01 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in the stock. Grantham Mayo Van Otterloo & Co. LLC bought a new stake in shares of Cardlytics in the 2nd quarter worth approximately $10,392,000. Bank of America Corp DE increased its position in shares of Cardlytics by 17.6% during the second quarter. Bank of America Corp DE now owns 338,915 shares of the company’s stock valued at $8,805,000 after purchasing an additional 50,621 shares during the period. Antipodean Advisors LLC bought a new stake in shares of Cardlytics during the second quarter valued at approximately $3,698,000. JPMorgan Chase & Co. increased its position in shares of Cardlytics by 177.9% during the second quarter. JPMorgan Chase & Co. now owns 199,301 shares of the company’s stock valued at $4,901,000 after purchasing an additional 127,596 shares during the period. Finally, Royal Bank of Canada raised its stake in shares of Cardlytics by 166.5% in the second quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock valued at $276,000 after purchasing an additional 6,649 shares in the last quarter. 93.17% of the stock is currently owned by institutional investors and hedge funds.
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
See Also: Blockchain
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.